There appears to be a recent uptrend in registered clinical trials studying psychedelics, which is similar to the recent increase in overall trials registered.

A growing body of evidence shows that psilocybin is safe and can relieve symptoms of depression and end-of-life demoralization in people with cancer and other life-threatening conditions.

Given the potential of psychedelic compounds to benefit older adults, more research is needed to establish safety and efficacy among older adults

This study was designed to review the brief history of the novel antidepressant arketamine, the molecular mechanisms underlying its antidepressant actions, and future directions.

Heavy drinking days decreased by about 80% among those in the psilocybin group.

LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms up to 16 weeks.

Psychedelic harm reduction services should consider how remote workers could be employed. There is a clear demand for remote psychedelic care services and to our knowledge this has not yet been explored.

We then apply this model to illuminate how experiences of awe that arise in nature, spirituality, music, collective movement, and psychedelics strengthen the mind and body.

After selection, 27 studies were included. Human studies (n = 20) generally show promising data and seem to indicate that classic psychedelics could help reduce alcohol consumption.

These data provide a detailed characterization and comparison of psychedelic occasioned and non-drug experiences that changed attitudes about death.

There is strong neurobiological plausibility for the hypothesis that chronic SSRI use dampens response to MDMA-assisted therapy.

Psilocybin administered in combination with psychotherapy produced robust decreases in percentage of heavy drinking days.

Among 1,435 participants, 72.5% never discussed psychedelic use with their primary care provider (PCP).